Jazz Pharmaceuticals JAZZ Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accrued liabilities, current?
- Jazz Pharmaceuticals (JAZZ) reported accrued liabilities, current of $1.02B in Q1 2026.
- How has Jazz Pharmaceuticals's accrued liabilities, current changed year-over-year?
- Jazz Pharmaceuticals's accrued liabilities, current decreased by 3.9% year-over-year, from $1.06B to $1.02B.
- What is the long-term trend for Jazz Pharmaceuticals's accrued liabilities, current?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accrued liabilities, current has grown at a 24.0% compound annual growth rate (CAGR), from $352.73M to $1.03B.